Caricamento...
EGFR and myosin II inhibitors cooperate to suppress EGFR‐T790M‐mutant NSCLC cells
An acquired mutation (T790M) in the epidermal growth factor receptor (EGFR) accounts for half of all relapses in non‐small cell lung cancer (NSCLC) patients who initially respond to EGFR kinase inhibitors. In this study, we demonstrated for the first time that EGFR‐T790M interacts with the cytoskele...
Salvato in:
| Pubblicato in: | Mol Oncol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528336/ https://ncbi.nlm.nih.gov/pubmed/22366308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.02.001 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|